Author

Rodrigo Almeida Toledo

Instituto de Salud Carlos IIIORCID 0000-0003-3070-6795Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Assay:scRNA-seq· 1 Research Focus:variant calling· 1

Frequent Co-Authors

Alba De MartinoiD· 1 shared Alexander R. OpotowskyiD· 1 shared Alexandre BuffetiD· 1 shared Álvaro OteroiD· 1 shared Amelia OleagaiD· 1 shared Ana Belén Moreno-CárdenasiD· 1 shared Ana González GarcíaiD· 1 shared Anand VaidyaiD· 1 shared

Activity by Year

2017-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenomics

Alba De MartinoORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCancer DiscoveryPeer-reviewedApr 8, 2025

Convergent genetic adaptation in human tumors developed under systemic hypoxia and in populations living at high altitudes

Carlota Arenillas, Lucía Celada, José Ruiz-Cantador…·Rodrigo Almeida Toledo

This study links EPAS1HIF2 genetic adaptations in high-altitude populations to similar mutations in hypoxia-driven tumors, showing shared mechanisms in hypoxia response and tumorigenesis.

14 citations

humanbulk RNA-seq

𝕏 PostBluesky

GenomicsbioRxivPreprintAug 28, 2017

Whole-exome sequencing of plasma cell-free DNA portrays the somatic mutation landscape of refractory metastatic colorectal cancer and enables the discovery of mutated KDR/VEGFR2 receptors as modulators of anti-angiogenic therapies.

Rodrigo Almeida Toledo, Elena Garralda, Maria Mitsi…·Manuel M. Hidalgo

This study uses whole-exome sequencing of plasma cell-free DNA to analyze somatic mutations in metastatic colorectal cancer and identifies KDR/VEGFR2 mutations affecting anti-angiogenic therapy response.

DOI 10.1101/177287

humanwhole-exome sequencing

𝕏 PostBluesky